Geoffrey Christopher Cloud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Geoffrey Christopher Cloud has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Natasha A. Lannin
School of Translational Medicine, Monash University
11 shared publications - Bruce C. V. Campbell
Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia
9 shared publications - Leonid Churilov
Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia
9 shared publications - Geoffrey Alan Donnan
Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Victoria, Australia (G.A.D.).
7 shared publications - Vincent Thijs
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia
7 shared publications Gagan Sharma
Department of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
6 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in Neurocritical Care
- p. 1-10
Management and Outcomes in Traumatic Cerebral Venous Sinus Thrombosis
- 27 October 2026
- Published by Springer Nature in Neurocritical Care
- p. 1-10
Management and Outcomes in Traumatic Cerebral Venous Sinus Thrombosis
- Open Access
- 13 October 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 111
Acute Ischaemic Stroke: Therapeutic Targets and Key Modulators of the Fibrinolytic System and Clot Formation
The processes of clot formation and clot dissolution with fibrinolysis underpin the pathophysiological mechanisms of acute ischaemic stroke (AIS) and its treatment. Detailed understanding of the modulation of this system is required to develop effective and safe stroke therapeutics. Clot formation occurs with the interaction of the coagulation cascade, along with platelets and fibrin meshwork. Conversely, fibrinolysis involves the serine protease plasmin, its zymogen, plasminogen and its enzymatic conversion by tissue plasminogen activator. The regulators and inhibitors that modulate the interactions in clot formation and fibrinolysis can be potential targets for new and emerging stroke therapies. The aim of this narrative review is to help inform stroke clinicians and researchers about the role of the fibrinolytic system and its inhibitors in AIS and the potential for new therapeutic targets. We outline the processes involved in clot formation and dissolution, the role of endogenous inhibitors of the fibrinolytic system, followed by potential therapeutic targets including tissue plasminogen activators as well as novel therapies and adjuncts. Better understanding of these processes will provide insight into the variable response to current stroke fibrinolytics amongst AIS patients and help to develop new and improved AIS therapeutics in future.
- 13 October 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 111
Open AccessAcute Ischaemic Stroke: Therapeutic Targets and Key Modulators of the Fibrinolytic System and Clot Formation
The processes of clot formation and clot dissolution with fibrinolysis underpin the pathophysiological mechanisms of acute ischaemic stroke (AIS) and its treatment. Detailed understanding of the modulation of this system is required to develop effective and safe stroke therapeutics. Clot formation occurs with the interaction of the coagulation cascade, along with platelets and fibrin meshwork. Conversely, fibrinolysis involves the serine protease plasmin, its zymogen, plasminogen and its enzymatic conversion by tissue plasminogen activator. The regulators and inhibitors that modulate the interactions in clot formation and fibrinolysis can be potential targets for new and emerging stroke therapies. The aim of this narrative review is to help inform stroke clinicians and researchers about the role of the fibrinolytic system and its inhibitors in AIS and the potential for new therapeutic targets. We outline the processes involved in clot formation and dissolution, the role of endogenous inhibitors of the fibrinolytic system, followed by potential therapeutic targets including tissue plasminogen activators as well as novel therapies and adjuncts. Better understanding of these processes will provide insight into the variable response to current stroke fibrinolytics amongst AIS patients and help to develop new and improved AIS therapeutics in future.
- 28 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6626-6636
Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase
Alteplase is synthesized as a single-chain protease that requires plasmin-mediated conversion to its fully active 2-chain form for maximal thrombolysis. Tenecteplase (TNK), an alteplase variant, is widely regarded as being more fibrin selective and more resistant to plasminogen activator inhibitor 1 (PAI-1) than alteplase. However, the PAI-1 sensitivity of TNK after 2-chain conversion and that of newly available TNK formulations has not been evaluated. Alteplase and 4 TNK formulations, Metalyse (Boehringer Ingelheim, Ingelheim am Rheim, Germany), Tenectase (Gennova, Pune, India), GenetPA (BioApower, Jiangsu, Yancheng, China), and Mingfule (CSPC Pharmaceutical Company Ltd, Guangdong, Guangzhou, China) were compared in their native state and after 2-chain conversion. Proteolytic activity and PAI-1 resistance and binding were evaluated using an amidolytic assay, fibrinolysis assays, and western blotting. Alteplase, but not Metalyse, was converted into its 2-chain form in plasma in a fibrinogen-dependent manner, resulting in off-target fibrinogenolysis. When directly reconstituted from the manufacturer’s vial (native form), TNK was approximately fourfold more resistant to PAI-1 than alteplase; however, 2-chain conversion significantly reduced PAI-1 resistance by ∼40%, concomitant with increased PAI-1 binding. Native Metalyse contained approximately threefold more preexisting 2-chain species than the other TNK formulations, explaining its higher amidolytic activity. However, after 2-chain conversion, all TNK formulations showed similar fibrinolytic activity, although with substantially reduced PAI-1 resistance. Metalyse and all new TNK formulations display similar fibrinolytic activity in their fully active 2-chain states, but this is associated with substantial loss of PAI-1 resistance, challenging the view that the fully active 2-chain form of TNK maintains PAI-1 resistance during thrombolysis.
- 28 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6626-6636
Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase
Alteplase is synthesized as a single-chain protease that requires plasmin-mediated conversion to its fully active 2-chain form for maximal thrombolysis. Tenecteplase (TNK), an alteplase variant, is widely regarded as being more fibrin selective and more resistant to plasminogen activator inhibitor 1 (PAI-1) than alteplase. However, the PAI-1 sensitivity of TNK after 2-chain conversion and that of newly available TNK formulations has not been evaluated. Alteplase and 4 TNK formulations, Metalyse (Boehringer Ingelheim, Ingelheim am Rheim, Germany), Tenectase (Gennova, Pune, India), GenetPA (BioApower, Jiangsu, Yancheng, China), and Mingfule (CSPC Pharmaceutical Company Ltd, Guangdong, Guangzhou, China) were compared in their native state and after 2-chain conversion. Proteolytic activity and PAI-1 resistance and binding were evaluated using an amidolytic assay, fibrinolysis assays, and western blotting. Alteplase, but not Metalyse, was converted into its 2-chain form in plasma in a fibrinogen-dependent manner, resulting in off-target fibrinogenolysis. When directly reconstituted from the manufacturer’s vial (native form), TNK was approximately fourfold more resistant to PAI-1 than alteplase; however, 2-chain conversion significantly reduced PAI-1 resistance by ∼40%, concomitant with increased PAI-1 binding. Native Metalyse contained approximately threefold more preexisting 2-chain species than the other TNK formulations, explaining its higher amidolytic activity. However, after 2-chain conversion, all TNK formulations showed similar fibrinolytic activity, although with substantially reduced PAI-1 resistance. Metalyse and all new TNK formulations display similar fibrinolytic activity in their fully active 2-chain states, but this is associated with substantial loss of PAI-1 resistance, challenging the view that the fully active 2-chain form of TNK maintains PAI-1 resistance during thrombolysis.
- Open Access
- 17 July 2026
- Published by SAGE Publications in International Journal of Stroke
Recovery-focused community support to avoid readmissions and improve participation after stroke: A multicenter randomized controlled trial
Background: Evidence is lacking on whether support and education programs, facilitated by mobile technology, benefit people with stroke. Aims: The primary aim was to determine the effectiveness of a co-designed, eHealth self-management intervention for reducing unplanned hospital presentations. Methods: Prospective, multicenter randomized controlled trial with blinded outcome assessment and intention-to-treat analysis. Randomization (1:1, stratified by age and level of disability at baseline) within 2 weeks of hospital discharge. Participants aged ⩾18 years with modified Rankin Scale (mRS) score 0–4 were recruited from 11 Australian hospitals. To maintain blinding, all participants co-developed three to five self-management goals with a trained clinician-researcher, using a standardized approach. Following randomization, participants were allocated to receive personalized, goal-centered electronic messages (intervention) or administrative messages (active control) over 12 weeks via text or email. The groups were not informed about the number of messages they would receive and were unaware that only the intervention group had their messages tailored to their goals. The primary outcome was unplanned hospital presentations (emergency department/admission) within 90 days post-randomization. Secondary outcomes included goal attainment, self-efficacy, and various health outcomes. We used generalized mixed-effects regression model with a logistic link for categorical outcomes and Cohen’s d (0.2 considered small effect, 0.5 moderate–1.0 large) to assess within-group change. Results: The trial was impacted by COVID-19 and ceased with 556/890 planned participants; 465 were randomized (n = 234 control, n = 231 experimental), a median of 10 days post-discharge (median age 67.2 years, 67.1% male, median 3 goals/participant). Primary outcome assessments for 222 control and 218 experimental participants showed no between-group differences for unplanned hospital presentations (odds ratio (OR): 1.32; 95% confidence interval (CI): 0.52–3.34). Compared to controls at 90 days, a larger proportion of the experimental group had >3 unmet needs and slight to severe disability (both <8% difference). Both groups showed non-significant improvements in goal attainment at 90 days post-randomization; overall attainment was stronger among intervention participants (within-group change Cohen’s d intervention 0.76 vs 0.61). Conclusion: We found no evidence that tailored, electronic messaging over 12 weeks, in addition to structured goal-setting reduced unplanned hospital presentations. Future research is needed to understand the role of disability and unmet needs, and factors that influence goal attainment. Trial registration: ACTRN12618001468213, U1111-1206-7237
- 17 July 2026
- Published by SAGE Publications in International Journal of Stroke
Open AccessRecovery-focused community support to avoid readmissions and improve participation after stroke: A multicenter randomized controlled trial
Background: Evidence is lacking on whether support and education programs, facilitated by mobile technology, benefit people with stroke. Aims: The primary aim was to determine the effectiveness of a co-designed, eHealth self-management intervention for reducing unplanned hospital presentations. Methods: Prospective, multicenter randomized controlled trial with blinded outcome assessment and intention-to-treat analysis. Randomization (1:1, stratified by age and level of disability at baseline) within 2 weeks of hospital discharge. Participants aged ⩾18 years with modified Rankin Scale (mRS) score 0–4 were recruited from 11 Australian hospitals. To maintain blinding, all participants co-developed three to five self-management goals with a trained clinician-researcher, using a standardized approach. Following randomization, participants were allocated to receive personalized, goal-centered electronic messages (intervention) or administrative messages (active control) over 12 weeks via text or email. The groups were not informed about the number of messages they would receive and were unaware that only the intervention group had their messages tailored to their goals. The primary outcome was unplanned hospital presentations (emergency department/admission) within 90 days post-randomization. Secondary outcomes included goal attainment, self-efficacy, and various health outcomes. We used generalized mixed-effects regression model with a logistic link for categorical outcomes and Cohen’s d (0.2 considered small effect, 0.5 moderate–1.0 large) to assess within-group change. Results: The trial was impacted by COVID-19 and ceased with 556/890 planned participants; 465 were randomized (n = 234 control, n = 231 experimental), a median of 10 days post-discharge (median age 67.2 years, 67.1% male, median 3 goals/participant). Primary outcome assessments for 222 control and 218 experimental participants showed no between-group differences for unplanned hospital presentations (odds ratio (OR): 1.32; 95% confidence interval (CI): 0.52–3.34). Compared to controls at 90 days, a larger proportion of the experimental group had >3 unmet needs and slight to severe disability (both <8% difference). Both groups showed non-significant improvements in goal attainment at 90 days post-randomization; overall attainment was stronger among intervention participants (within-group change Cohen’s d intervention 0.76 vs 0.61). Conclusion: We found no evidence that tailored, electronic messaging over 12 weeks, in addition to structured goal-setting reduced unplanned hospital presentations. Future research is needed to understand the role of disability and unmet needs, and factors that influence goal attainment. Trial registration: ACTRN12618001468213, U1111-1206-7237
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2098-2107
Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke
BACKGROUND: Low-dose aspirin is no longer recommended for routine primary prevention in older adults due to bleeding risks outweighing vascular benefits. We hypothesized that an integrative polygenic score (iPGS) could identify a subgroup of older individuals who derive net benefit from aspirin for the primary prevention of ischemic stroke. METHODS: We performed post hoc analysis of the ASPREE randomized, placebo-controlled trial (Aspirin in Reducing Events in the Elderly) of daily 100-mg aspirin, in 12 031 genotyped participants of European ancestry aged >70 years without prior cardiovascular disease. The iPGS was derived from >1.2 million variants and evaluated both continuously and by quintiles. Cox models assessed associations between polygenic risk, ischemic stroke, and major bleeding events, and tested the interaction between the iPGS and treatment allocation, with adjustment for baseline lifestyle and clinical covariates. RESULTS: The mean age of participants was 75.1 years, and 54.9% were women. Over a median of 4.6 years, 187 ischemic strokes and 373 major bleeds occurred, including 101 intracranial bleeds (46 hemorrhagic strokes). Each 1-SD increase in the iPGS was associated with higher incident ischemic stroke risk (hazard ratio, 1.39 [95% CI, 1.20–1.62]). An interaction between the continuous iPGS and aspirin allocation was observed for ischemic stroke ( P =0.04) but not major bleeding. In the highest iPGS quintile, aspirin reduced ischemic stroke by 51% (hazard ratio, 0.49 [95% CI, 0.28–0.85]) without significantly increasing major bleeding (hazard ratio, 1.15 [95% CI, 0.71–1.88]). No benefit was observed in the overall cohort or in lower-risk quintiles. CONCLUSIONS: Among older adults, high polygenic risk identifies individuals who may experience substantial stroke reduction with aspirin, with no excess bleeding. These findings raise the possibility that genomic risk stratification may enable targeted aspirin use for the primary prevention of ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2098-2107
Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke
BACKGROUND: Low-dose aspirin is no longer recommended for routine primary prevention in older adults due to bleeding risks outweighing vascular benefits. We hypothesized that an integrative polygenic score (iPGS) could identify a subgroup of older individuals who derive net benefit from aspirin for the primary prevention of ischemic stroke. METHODS: We performed post hoc analysis of the ASPREE randomized, placebo-controlled trial (Aspirin in Reducing Events in the Elderly) of daily 100-mg aspirin, in 12 031 genotyped participants of European ancestry aged >70 years without prior cardiovascular disease. The iPGS was derived from >1.2 million variants and evaluated both continuously and by quintiles. Cox models assessed associations between polygenic risk, ischemic stroke, and major bleeding events, and tested the interaction between the iPGS and treatment allocation, with adjustment for baseline lifestyle and clinical covariates. RESULTS: The mean age of participants was 75.1 years, and 54.9% were women. Over a median of 4.6 years, 187 ischemic strokes and 373 major bleeds occurred, including 101 intracranial bleeds (46 hemorrhagic strokes). Each 1-SD increase in the iPGS was associated with higher incident ischemic stroke risk (hazard ratio, 1.39 [95% CI, 1.20–1.62]). An interaction between the continuous iPGS and aspirin allocation was observed for ischemic stroke ( P =0.04) but not major bleeding. In the highest iPGS quintile, aspirin reduced ischemic stroke by 51% (hazard ratio, 0.49 [95% CI, 0.28–0.85]) without significantly increasing major bleeding (hazard ratio, 1.15 [95% CI, 0.71–1.88]). No benefit was observed in the overall cohort or in lower-risk quintiles. CONCLUSIONS: Among older adults, high polygenic risk identifies individuals who may experience substantial stroke reduction with aspirin, with no excess bleeding. These findings raise the possibility that genomic risk stratification may enable targeted aspirin use for the primary prevention of ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583.
- Open Access
Heterogeneity of Treatment Effect of Aspirin and Clinically Significant Bleeding in Older Adults
Aim: The global population of older adults is growing, and older age is linked to higher bleeding risk. Although guidelines discourage aspirin for primary prevention in healthy older adults due to bleeding harms outweighing benefits, many continue taking it without a clear indication. It remains unclear whether all older adults face uniform aspirin-related bleeding risk or if certain subgroups are more vulnerable. Methods: We analyzed data from 19,114 ASPREE trial participants to develop machine learning models using 116 baseline variables. Random forest (RF) and random survival forest (RSF) models predicted 5-year bleeding risk, and participants were stratified into low, intermediate, and high-risk groups based on the 20th and 80th percentiles of predicted risk. We assessed heterogeneity of treatment effect (HTE) by testing treatment-by-risk group interactions on the relative scale using Fine-Gray models, and on the absolute scale using observed 5-year cumulative incidence rates. Results: Over a median follow-up of 4.7 years, 626 major bleeding events occurred. The RF model had moderate discrimination (AUC = 0.65, 95% CI: 0.63-0.67) and good calibration (Brier = 0.032, 95% CI: 0.029-0.034). Statistically significant HTE was observed on the relative scale, with the greatest relative increase in bleeding risk seen in the low-risk group (subdistribution hazard ratio = 2.26, 95% CI: 1.27–4.01). On the absolute scale, low-risk participants experienced higher bleeding with aspirin (absolute risk difference (ARD) = 1.17%, 95% CI: 0.37–1.95), but heterogeneity in ARDs was not statistically significant (Cochran’s Q p > 0.45). Similar findings were observed when using the RSF model. Conclusion: Participants at lowest baseline bleeding risk experienced the greatest relative increase in bleeding risk with aspirin therapy. We found statistically significant heterogeneity in treatment effects on the relative but not absolute scale. These findings support an individualized, risk-based approach to aspirin therapy decision-making in older adults.
Open AccessHeterogeneity of Treatment Effect of Aspirin and Clinically Significant Bleeding in Older Adults
Aim: The global population of older adults is growing, and older age is linked to higher bleeding risk. Although guidelines discourage aspirin for primary prevention in healthy older adults due to bleeding harms outweighing benefits, many continue taking it without a clear indication. It remains unclear whether all older adults face uniform aspirin-related bleeding risk or if certain subgroups are more vulnerable. Methods: We analyzed data from 19,114 ASPREE trial participants to develop machine learning models using 116 baseline variables. Random forest (RF) and random survival forest (RSF) models predicted 5-year bleeding risk, and participants were stratified into low, intermediate, and high-risk groups based on the 20th and 80th percentiles of predicted risk. We assessed heterogeneity of treatment effect (HTE) by testing treatment-by-risk group interactions on the relative scale using Fine-Gray models, and on the absolute scale using observed 5-year cumulative incidence rates. Results: Over a median follow-up of 4.7 years, 626 major bleeding events occurred. The RF model had moderate discrimination (AUC = 0.65, 95% CI: 0.63-0.67) and good calibration (Brier = 0.032, 95% CI: 0.029-0.034). Statistically significant HTE was observed on the relative scale, with the greatest relative increase in bleeding risk seen in the low-risk group (subdistribution hazard ratio = 2.26, 95% CI: 1.27–4.01). On the absolute scale, low-risk participants experienced higher bleeding with aspirin (absolute risk difference (ARD) = 1.17%, 95% CI: 0.37–1.95), but heterogeneity in ARDs was not statistically significant (Cochran’s Q p > 0.45). Similar findings were observed when using the RSF model. Conclusion: Participants at lowest baseline bleeding risk experienced the greatest relative increase in bleeding risk with aspirin therapy. We found statistically significant heterogeneity in treatment effects on the relative but not absolute scale. These findings support an individualized, risk-based approach to aspirin therapy decision-making in older adults.
- Open Access
- 1 January 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (1) , e001571
Foreign body-type giant cell reaction post intracranial endovascular clot retrieval: a postmortem case
Background and aims: Endovascular clot retrieval (ECR) has revolutionised acute ischaemic stroke management. While procedural safety is well established, little attention has been paid to vascular responses to hydrophilic polymer coatings used on retrieval devices. This report presents postmortem histopathological findings implicating a foreign body giant cell reaction secondary to hydrophilic polymer exposure as a cause of recurrent stroke following ECR. Methods: A detailed clinical and neuropathological review was conducted on a 72-year-old patient who experienced three sequential ischaemic strokes within 4 months following ECR and angioplasty of a right middle cerebral artery (M2) occlusion. Limited postmortem examination of the heart and brain was undertaken with histopathological and immunoperoxidase staining to assess potential vascular inflammatory mechanisms. Results: Postmortem examination demonstrated multiple infarcts of differing ages, diffuse atherosclerotic change and a florid multinucleated giant cell reaction containing non-polarisable basophilic material along the luminal surface of the right M2 segment and adjacent vessels. The internal elastic lamina remained intact, with only focal fibrinoid necrosis and sparse medial inflammation. No amyloid angiopathy, vasculitis or cardiac embolic source was identified. The morphological features were consistent with a chronic inflammatory response to embolised hydrophilic polymer coating material from prior endovascular instrumentation. Conclusions: This case highlights an under-recognised mechanism of post-ECR recurrent stroke linked to hydrophilic polymer-induced vascular inflammation. If recognised antemortem, immunosuppression may be more effective than usual secondary stroke prevention treatments.
- 1 January 2026
- Published by BMJ in BMJ Neurology Open
- Vol. 8 (1) , e001571
Open AccessForeign body-type giant cell reaction post intracranial endovascular clot retrieval: a postmortem case
Background and aims: Endovascular clot retrieval (ECR) has revolutionised acute ischaemic stroke management. While procedural safety is well established, little attention has been paid to vascular responses to hydrophilic polymer coatings used on retrieval devices. This report presents postmortem histopathological findings implicating a foreign body giant cell reaction secondary to hydrophilic polymer exposure as a cause of recurrent stroke following ECR. Methods: A detailed clinical and neuropathological review was conducted on a 72-year-old patient who experienced three sequential ischaemic strokes within 4 months following ECR and angioplasty of a right middle cerebral artery (M2) occlusion. Limited postmortem examination of the heart and brain was undertaken with histopathological and immunoperoxidase staining to assess potential vascular inflammatory mechanisms. Results: Postmortem examination demonstrated multiple infarcts of differing ages, diffuse atherosclerotic change and a florid multinucleated giant cell reaction containing non-polarisable basophilic material along the luminal surface of the right M2 segment and adjacent vessels. The internal elastic lamina remained intact, with only focal fibrinoid necrosis and sparse medial inflammation. No amyloid angiopathy, vasculitis or cardiac embolic source was identified. The morphological features were consistent with a chronic inflammatory response to embolised hydrophilic polymer coating material from prior endovascular instrumentation. Conclusions: This case highlights an under-recognised mechanism of post-ECR recurrent stroke linked to hydrophilic polymer-induced vascular inflammation. If recognised antemortem, immunosuppression may be more effective than usual secondary stroke prevention treatments.
- Open Access
- 5 December 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (6) , 861-870
Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1)
Background: Rinvecalinase alfa (DM199), a recombinant form of human tissue kallikrein-1 (KLK1), aims to promote local vasodilation to ischemic brain and enhance collateral blood flow. The ReMEDy1 trial tested the safety and tolerability of rinvecalinase alfa in ischemic stroke. Methods: ReMEDy1 was a phase II, randomized, double-blind, placebo-controlled, study conducted at 13 Australian sites. Ninety-two patients with NIH Stroke Scale (NIHSS) 6–25 were enrolled within 24 h of ischemic stroke onset. Patients were randomized 1:1 to receive rinvecalinase alfa (1 µg/kg intravenous infusion followed by 3 µg/kg subcutaneously every 3 days for 22 days) or placebo. The primary outcome was safety, assessed by adverse events (AEs) and serious adverse events (SAEs). Secondary outcomes included changes in NIHSS, modified Rankin Scale (mRS), and Barthel Index (BI) at Days 22 and 90. Post hoc analyses excluded patients who underwent endovascular therapy (EVT). Results: The median age was 72, NIHSS 10, and onset-to-randomization was 19.5 h. SAEs were reported in 20/47 (43.5%) rinvecalinase alfa patients and 14/45 (31.1%) placebo patients. Most patients experienced at least one AE; the most common in the rinvecalinase alfa group were constipation (60.9%), oral candidiasis (23.9%), and nausea (17.4%). Stroke-in-evolution by Day 90 occurred in 0 (0%) rinvecalinase alfa patients versus 6 (13.3%) placebo patients; 4/6 (66.7%) placebo patients with stroke-in-evolution died. No significant differences were observed in secondary efficacy outcomes at Day 90. Post hoc analyses in patients not treated with EVT suggested a tendency toward improved excellent global outcomes with rinvecalinase alfa. Conclusions: Rinvecalinase alfa appeared to be safe and generally well-tolerated in ischemic stroke patients, with potential efficacy in reducing stroke progression. Further studies are needed to confirm efficacy and long-term benefits in patients without EVT. Registrations: https://www.clinicaltrials.gov/study/NCT03290560
- 5 December 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (6) , 861-870
Open AccessSafety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1)
Background: Rinvecalinase alfa (DM199), a recombinant form of human tissue kallikrein-1 (KLK1), aims to promote local vasodilation to ischemic brain and enhance collateral blood flow. The ReMEDy1 trial tested the safety and tolerability of rinvecalinase alfa in ischemic stroke. Methods: ReMEDy1 was a phase II, randomized, double-blind, placebo-controlled, study conducted at 13 Australian sites. Ninety-two patients with NIH Stroke Scale (NIHSS) 6–25 were enrolled within 24 h of ischemic stroke onset. Patients were randomized 1:1 to receive rinvecalinase alfa (1 µg/kg intravenous infusion followed by 3 µg/kg subcutaneously every 3 days for 22 days) or placebo. The primary outcome was safety, assessed by adverse events (AEs) and serious adverse events (SAEs). Secondary outcomes included changes in NIHSS, modified Rankin Scale (mRS), and Barthel Index (BI) at Days 22 and 90. Post hoc analyses excluded patients who underwent endovascular therapy (EVT). Results: The median age was 72, NIHSS 10, and onset-to-randomization was 19.5 h. SAEs were reported in 20/47 (43.5%) rinvecalinase alfa patients and 14/45 (31.1%) placebo patients. Most patients experienced at least one AE; the most common in the rinvecalinase alfa group were constipation (60.9%), oral candidiasis (23.9%), and nausea (17.4%). Stroke-in-evolution by Day 90 occurred in 0 (0%) rinvecalinase alfa patients versus 6 (13.3%) placebo patients; 4/6 (66.7%) placebo patients with stroke-in-evolution died. No significant differences were observed in secondary efficacy outcomes at Day 90. Post hoc analyses in patients not treated with EVT suggested a tendency toward improved excellent global outcomes with rinvecalinase alfa. Conclusions: Rinvecalinase alfa appeared to be safe and generally well-tolerated in ischemic stroke patients, with potential efficacy in reducing stroke progression. Further studies are needed to confirm efficacy and long-term benefits in patients without EVT. Registrations: https://www.clinicaltrials.gov/study/NCT03290560
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213981
Safety and Efficacy of Perispinal Etanercept for Chronic Stroke
Stroke is a leading cause of long-term disability. Etanercept, a competitive tumor necrosis factor-α inhibitor, has been proposed as a potential treatment for post-stroke impairments when given through a perispinal subcutaneous injection. We aimed to evaluate the safety and efficacy of perispinal etanercept in patients with chronic stroke. The Perispinal Etanercept for Stroke Outcomes Study was a randomized, double-blind, placebo-controlled, parallel group trial conducted in 3 ambulatory research clinics in Australia and New Zealand. Eligible patients were aged between 18 and 70 years, had a stroke between 1 and 15 years before enrollment, had a modified Rankin Scale score of 2-5, and demonstrated reduced quality of life as assessed by the 36-Item Short Form Survey (SF-36). Patients were randomized in a 1:1 ratio. The primary outcome was the difference in the proportion of participants at day 28 with an improvement of 5 points or more on the SF-36v2 compared with baseline after a single injection of etanercept 25 mg or equivalent placebo. The primary safety outcome was the difference in the proportion over 28 days of serious adverse events after a single injection of etanercept 25 mg or equivalent placebo. The primary outcome and safety were analyzed in the intention-to-treat population. Participants were followed up 56 days after the first injection of perispinal etanercept. Recruitment ceased early because of lack of continued funding. We screened 147 participants, of whom 126 were enrolled and randomized (63 etanercept: 63 placebo; 48 [38%] female, median (interquartile range) age 54.5 (45.0-60.0) years, median time since stroke 3 years). The primary outcome of improvement occurred in 33 of 63 participants (53%) in the etanercept arm and 36 of 63 participants (58%) in the placebo arm (adjusted odds ratio 0.82, 95% CI 0.40-1.67, standardized risk difference -5%, 95% CI -22% to 13%). The proportion of serious adverse events was similar in both treatment arms. Perispinal etanercept was safe, but we found no evidence of improvement in quality of life and other efficacy outcomes compared with placebo. The trial was registered at anzctr.org.au (ACTRN12620001011976) on October 7, 2020. Patients were enrolled between November 4, 2020, and September 1, 2023. This study provides Class I evidence that in patients with imaging-confirmed ischemic or hemorrhagic stroke, perispinal etanercept (25 mg) injection does not improve the patients' quality of life 28 days after injection.
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213981
Open AccessSafety and Efficacy of Perispinal Etanercept for Chronic Stroke
Stroke is a leading cause of long-term disability. Etanercept, a competitive tumor necrosis factor-α inhibitor, has been proposed as a potential treatment for post-stroke impairments when given through a perispinal subcutaneous injection. We aimed to evaluate the safety and efficacy of perispinal etanercept in patients with chronic stroke. The Perispinal Etanercept for Stroke Outcomes Study was a randomized, double-blind, placebo-controlled, parallel group trial conducted in 3 ambulatory research clinics in Australia and New Zealand. Eligible patients were aged between 18 and 70 years, had a stroke between 1 and 15 years before enrollment, had a modified Rankin Scale score of 2-5, and demonstrated reduced quality of life as assessed by the 36-Item Short Form Survey (SF-36). Patients were randomized in a 1:1 ratio. The primary outcome was the difference in the proportion of participants at day 28 with an improvement of 5 points or more on the SF-36v2 compared with baseline after a single injection of etanercept 25 mg or equivalent placebo. The primary safety outcome was the difference in the proportion over 28 days of serious adverse events after a single injection of etanercept 25 mg or equivalent placebo. The primary outcome and safety were analyzed in the intention-to-treat population. Participants were followed up 56 days after the first injection of perispinal etanercept. Recruitment ceased early because of lack of continued funding. We screened 147 participants, of whom 126 were enrolled and randomized (63 etanercept: 63 placebo; 48 [38%] female, median (interquartile range) age 54.5 (45.0-60.0) years, median time since stroke 3 years). The primary outcome of improvement occurred in 33 of 63 participants (53%) in the etanercept arm and 36 of 63 participants (58%) in the placebo arm (adjusted odds ratio 0.82, 95% CI 0.40-1.67, standardized risk difference -5%, 95% CI -22% to 13%). The proportion of serious adverse events was similar in both treatment arms. Perispinal etanercept was safe, but we found no evidence of improvement in quality of life and other efficacy outcomes compared with placebo. The trial was registered at anzctr.org.au (ACTRN12620001011976) on October 7, 2020. Patients were enrolled between November 4, 2020, and September 1, 2023. This study provides Class I evidence that in patients with imaging-confirmed ischemic or hemorrhagic stroke, perispinal etanercept (25 mg) injection does not improve the patients' quality of life 28 days after injection.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1600-1611
Proteinopathies and the Neurodegenerative Aftermath of Stroke: Potential Biomarkers and Treatment Targets
Stroke remains a predominant cause of death and long-term disability among adults worldwide. Emerging evidence suggests that proteinopathies, characterized by the aggregation and accumulation of misfolded proteins, may play a significant role in the aftermath of stroke and the progression of neurodegenerative disorders. In this review, we explore preclinical and clinical research on key proteinopathies associated with stroke, including tau, Aβ (amyloid-β), TDP-43 (TAR DNA-binding protein 43), α-synuclein, and UCH-L1 (ubiquitin C-terminal hydrolase-L1). We focus on their potential as biomarkers for recovery management and as novel treatment targets that may enhance neuronal repair and mitigate secondary neurodegeneration. The involvement of these proteinopathies in various aspects of stroke, including neuroinflammation, oxidative stress, neuronal damage, and vascular dysfunction, underscores their potential. However, further investigations are essential to validate the clinical utility of these biomarkers, elucidate the mechanisms connecting proteinopathies to poststroke neurodegeneration, and develop targeted interventions. Identifying specific protein signatures associated with stroke outcomes could facilitate the advancement of precision medicine tailored to individual patient needs, significantly enhancing the quality of life for stroke survivors.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1600-1611
Proteinopathies and the Neurodegenerative Aftermath of Stroke: Potential Biomarkers and Treatment Targets
Stroke remains a predominant cause of death and long-term disability among adults worldwide. Emerging evidence suggests that proteinopathies, characterized by the aggregation and accumulation of misfolded proteins, may play a significant role in the aftermath of stroke and the progression of neurodegenerative disorders. In this review, we explore preclinical and clinical research on key proteinopathies associated with stroke, including tau, Aβ (amyloid-β), TDP-43 (TAR DNA-binding protein 43), α-synuclein, and UCH-L1 (ubiquitin C-terminal hydrolase-L1). We focus on their potential as biomarkers for recovery management and as novel treatment targets that may enhance neuronal repair and mitigate secondary neurodegeneration. The involvement of these proteinopathies in various aspects of stroke, including neuroinflammation, oxidative stress, neuronal damage, and vascular dysfunction, underscores their potential. However, further investigations are essential to validate the clinical utility of these biomarkers, elucidate the mechanisms connecting proteinopathies to poststroke neurodegeneration, and develop targeted interventions. Identifying specific protein signatures associated with stroke outcomes could facilitate the advancement of precision medicine tailored to individual patient needs, significantly enhancing the quality of life for stroke survivors.